Dr. Zhiyang Zhao

Biography

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) of Alliance Pharma. Dr. Zhao has over 20 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. For the past 11 years, Dr. Zhao served as Site Director for Preclinical Studies at Amgen in Cambridge, Massachusetts. Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50  peer‑reviewed scientific publications and 4   patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology. Currently, Dr. Zhao also holds an appointment as Adjunct Professor at the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, North Carolina, and serves as Editor-in-Chief of Drug Metabolism Letters, a journal by Bentham Science, which publishes short papers on major advances in all areas of drug metabolism and disposition. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.         Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) of Alliance Pharma. Dr. Zhao has over 20 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. For the past 11 years, Dr. Zhao served as Site Director for Preclinical Studies at Amgen in Cambridge, Massachusetts. Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50  peer‑reviewed scientific publications and 4   patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology. Currently, Dr. Zhao also holds an appointment as Adjunct Professor at the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, North Carolina, and serves as Editor-in-Chief of Drug Metabolism Letters, a journal by Bentham Science, which publishes short papers on major advances in all areas of drug metabolism and disposition. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.        

Research Interest

Host defense mechanisms,LPS effects on neurotransmitters